What LGC Clinical Diagnostics does

LGC Clinical Diagnostics is a business unit of LGC Group that develops and manufactures diagnostic quality measurement tools, reference materials, and reagent components for the in vitro diagnostics (IVD) industry and clinical laboratory market. The company operates as a multi-brand portfolio built through bolt-on acquisitions, comprising six brands: Technopath Clinical Diagnostics (consolidated QC materials and IAMQC informatics software), SeraCare (ACCURUN® serology controls and Seraseq® NGS reference materials for oncology, NIPT, and inherited disease), Biochemical Diagnostics (DETECTABUSE® and STAT-SKREEN® drugs-of-abuse controls), Kova International (Kova-Trol® and Kova-LiquaTrol® urinalysis controls), Maine Standards (VALIDATE® calibration verification kits), and The Native Antigen Company (viral and bacterial antigens and antibodies produced via the proprietary VirtuE™ expression system). Its products serve IVD manufacturers, clinical laboratories, clinical research organizations, academic institutions, physician office laboratories, medical examiners, and pain management centers across more than 100 countries with an installed base of over 20,000 customers.

The company generates revenue primarily through one-time license/sale of catalog and custom-developed QC materials, reference standards, and biological reagents. Manufacturing is performed across FDA-registered, ISO 13485- and ISO 9001-certified, cGMP-qualified facilities in the US (Milford, Garden Grove, Edgewood), UK (Teddington, Kidlington), and Ireland (Tipperary). Go-to-market is enterprise field sales with direct engagement, supplemented by digital content marketing, webinars, and a website-driven inquiry channel. Certifications and the deep regulatory integration of its products into validated laboratory workflows constitute the company's primary competitive position, with growth executed predominantly through serial acquisitions of complementary QC and reagent brands integrated under a common umbrella.

LGC Clinical Diagnostics is wholly owned by LGC Group, a privately held life sciences tools conglomerate with 175+ years of heritage (registered in England). Operational scale spans 1,001–5,000 employees, with the identified executive leader being Bharathi Anekella, Executive Vice President & General Manager. The acquisition cadence of 2015 (Maine Standards), 2018 (SeraCare), 2020 (The Native Antigen Company), 2021 (Technopath), and 2023 (Kova International plus Biochemical Diagnostics) defines the unit's growth trajectory; no independent equity or debt funding rounds are disclosed for the unit itself, as capital is supplied at the parent-group level.

Name

LGC Clinical Diagnostics

Legal name

LGC Clinical Diagnostics

Website

https://lgcclinicaldiagnostics.com

Company type

Private

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

LGC Clinical Diagnostics is a multi-brand manufacturer of diagnostic quality controls, reference materials, and biological reagents (antigens and antibodies) for IVD manufacturers, clinical laboratories, CROs, and academic institutions across 100+ countries, wholly owned by LGC Group.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics Quality Controls and Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)

akta.pro secondary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Diagnostic quality controls
• Reagent components
• Calibration verification materials
• NGS reference materials
• Infectious disease antigens

Headquarters

HQ city

Milford

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Quality Management Tools (QMT): LGC Clinical Diagnostics manufactures and sells Quality Management Tools including independent quality controls, calibration verification materials, and QC data management software to clinical laboratories and IVD manufacturers.
2. Reagent Components and Biological Materials: Manufacturing and supply of reagent components, biological materials, viral and bacterial antigens/antibodies for diagnostic development and clinical testing applications.
3. Reference Materials: Supply of reference materials including ACCURUN® controls, Seraseq® NGS reference materials, and customizable biological materials for assay development, validation, and quality control monitoring.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

LGC Clinical Diagnostics develops, manufactures, and supplies diagnostic quality management tools—including independent third-party quality controls, calibration verification materials, linearity kits, and QC data management software—together with reagent components and biological materials (viral and bacterial antigens, antibodies, NGS reference materials) for In Vitro Diagnostics manufacturers, clinical laboratories, and clinical research organizations. Its offering spans clinical chemistry, immunochemistry, serology, molecular diagnostics, clinical genomics, urinalysis, toxicology, and proficiency testing, delivered through six specialized brands consolidated under a single FDA-registered, ISO 13485-certified manufacturing footprint in the US, Ireland, and UK.

Product overview

LGC Clinical Diagnostics operates as a multi-brand portfolio company offering Quality Management Tools (QMT) and reagent components for the In Vitro Diagnostics industry. The portfolio consists of six distinct acquired brands: Technopath Clinical Diagnostics (Independent Quality Controls & QC Data Management Software including Multichem® QC and IAMQC), SeraCare (Quality Measurement Tools including ACCURUN® controls and Seraseq® NGS reference materials for oncology, NIPT, and inherited disease), Biochemical Diagnostics (Drugs of Abuse Quality Controls including DETECTABUSE®, STAT-SKREEN®, PREGNANCY-SKREEN™), Kova International (Urinalysis Quality Controls including Kova-Trol®, Kova-LiquaTrol®, Kova® poc), Maine Standards (Linearity and Calibration Verification including VALIDATE® kits), and The Native Antigen Company (Antigens and Antibodies using the proprietary VirtuE™ expression system). Combined capabilities span clinical chemistry, immunochemistry, serology, molecular diagnostics, and clinical genomics. The company also offers Certus External Quality Assessment (EQA) for international proficiency testing.

Differentiator

Problem solved

Functional benefit

Brands

• Technopath Clinical Diagnostics: Independent Quality Controls & QC Software Solutions — manufacturer of consolidated QC materials including the Multichem® QC range and IAMQC informatics software.
• SeraCare
• Biochemical Diagnostics
• Kova International
• Maine Standards
• The Native Antigen Company

Products and services

• Multichem® Class-leading, third-party, test-consolidated quality control product range covering an extensive list of analytes for clinical chemistry and immunoassay, including the first barcoded QC material storable directly on-board laboratory instruments.
• ACCURUN® Quality control reagents designed to be weakly reactive to monitor serology assays and provide additional confidence in laboratory test results.
• Seraseq®

Named customers7 records

Segments7 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• LGC GroupcoreOthersLGC Clinical Diagnostics is a business unit of LGC Group, a leading global life science tools company. LGC Group provides mission-critical components and solutions into high-growth application areas across human healthcare and applied market segments, with 175+ years of scientific heritage. The company's track record of innovation and value-enhancing acquisitions has enabled it to build deep relationships with customers, industry partners, and the global scientific community.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sekisui Diagnostics: Sekisui Diagnostics offers clinical chemistry QC materials and reference controls alongside its OSOM rapid diagnostic tests, overlapping directly with LGC's chemistry and immunoassay QC portfolio.
• Microbiologics: Microbiologics produces biological reference materials and QC microorganisms for clinical and molecular labs, comparable to LGC's infectious disease and molecular reference material offerings.
• Bio-Rad Laboratories: Bio-Rad's Life Science and Clinical Diagnostics segments compete directly with LGC in third-party QC materials, calibration verification, and immunoassay controls for clinical laboratories worldwide.
• Streck: Streck manufactures QC and reference materials for hematology, molecular diagnostics, and infectious disease, directly overlapping with LGC's SeraCare and Native Antigen product lines.
• Randox Laboratories: Randox is a global manufacturer of clinical chemistry QC (Acusera), reagents, and molecular diagnostics controls, competing with LGC's Multichem and Biochemical Diagnostics ranges.

Broad incumbents

• Thermo Fisher Scientific: Thermo Fisher's Specialty Diagnostics and life sciences businesses supply QC, reference materials, and biological reagents to clinical labs, with comparable scope and reach to LGC Clinical Diagnostics.
• Roche Diagnostics: Roche Diagnostics is a global IVD leader with integrated QC and reagent offerings, providing competition to LGC across clinical chemistry, immunoassay, molecular, and clinical genomics segments.
• Siemens Healthineers: Siemens Healthineers offers integrated IVD systems, reagents, and QC consumables for clinical labs; its portfolio competes broadly with LGC's reagent components and quality controls.
• QuidelOrtho: QuidelOrtho is a broad IVD manufacturer spanning immunoassays, molecular diagnostics, and specialty testing; its QC consumables overlap with LGC's reagent components business.
• Abbott Diagnostics: Abbott Diagnostics operates one of the largest IVD platforms globally and supplies both reagents and QC materials, competing with LGC across chemistry, immunoassay, and molecular.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lgc-clinical-diagnostics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LGC Clinical Diagnostics